Palandri, Francesca
Benevolo, Giulia
Iurlo, Alessandra
Abruzzese, Elisabetta
Carella, Angelo M.
Paoli, Chiara
Palumbo, Giuseppe A.
Bonifacio, Massimiliano
Cilloni, Daniela
Andriani, Alessandro
Guarini, Attilio
Turri, Diamante
Elli, Elena Maria
Falcone, Antonietta
Anaclerico, Barbara
Musto, Pellegrino
Di Renzo, Nicola
Tiribelli, Mario
Zambello, Renato
Spinosa, Caterina
Ricco, Alessandra
Raucci, Letizia
Martino, Bruno
Annunziata, Mario
Pascale, Silvia
Liberati, Anna Marina
La Nasa, Giorgio
Maffioli, Margherita
Breccia, Massimo
Pugliese, Novella
Betti, Silvia
Giglio, Gianfranco
Cappuccio, Antonietta
Reale, Luigi http://orcid.org/0000-0003-4318-8608
Article History
Accepted: 1 March 2018
First Online: 8 March 2018
Compliance with ethical standards
:
: A. Iurlo has acted a consultant for and received honoraria from Novartis; M. Pellegrino has received honoraria from Novartis, as producer of deferasirox and ruxolitinib that are agents used for the treatment of myelofibrosis; M.Breccia has received honoraria from Novartis, BMS, Pfizer and Incyte; M. Bonifacio has received research fundings from Novartis; all other authors declared no conflict of interests.
: Informed consent was obtained from all individual participants included in the study.